Full-Time

VP – Development

Precision Medicine

Posted on 4/5/2025

Telix Pharmaceuticals

Telix Pharmaceuticals

501-1,000 employees

Develops targeted radiation therapies for cancer

No salary listed

Expert

Remote in Canada

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Master’s degree in Scientific field required
  • PhD preferred
  • Minimum of 10+ years in escalating management roles focused on global product development within the pharma/biotech sphere
  • Background in oncology drug development required
  • Radiopharmaceuticals experience is highly desirable
  • Prior experience in direct leadership and people management required
  • Exceptional verbal and written communication capabilities, adept at interfacing with senior-level stakeholders
  • Demonstrated ability to think strategically, foreseeing and addressing challenges related to transitioning from early to late-stage development
Responsibilities
  • Direct development strategies, ensuring successful progression of investigational products through to global commercialization and lifecycle management
  • Foster a collaborative environment where team members are driven by both science and business to improve patient lives
  • Engage with senior and executive management to ensure that programs are adequately resourced and aligned with business objectives
  • Articulate a clear vision for program success and emphasize principles that prioritize patients and quality
  • Contribute significantly to the overall portfolio development strategy, ensuring alignment with corporate objectives
  • Collaborate with leadership from Commercial, Therapeutic product development, Clinical, Manufacturing, and other key functions to align strategically, drive progress to milestones, and proactively address issues and risks
  • Work in close association with the Regulatory Affairs function to optimize regulatory agency interactions and achieve product approvals in line with target product profiles
  • Spearhead new development opportunities encompassing geographic and label expansion, lifecycle management, and due diligences
  • Advocate for the company's values and behaviors, overseeing career progression of direct reports, including recruitment, training, mentoring, and performance management, ensuring a high-performing matrix environment
Desired Qualifications
  • Demonstrate an understanding and appreciation for diversity, and actively work to create an inclusive environment where everyone feels valued and respected
  • Possess a willingness to think outside the box and come up with unique and creative solutions to challenges
  • Take pride in your work and consistently strive for excellence in everything you do
  • Driven to achieve goals and objectives, with a strong focus on delivering measurable results
  • Act with integrity and demonstrate a commitment to ethical behavior in all interactions with colleagues and stakeholders
  • Comfortable working in a dynamic environment, able to adjust to changing priorities, and willing to take on new challenges
  • Able to communicate effectively with colleagues and stakeholders at all levels, using clear and concise language
  • Work effectively as part of a team, actively sharing knowledge and expertise to achieve common goals
  • Demonstrate the ability to bounce back from setbacks and persevere in the face of challenges
  • Show a commitment to ongoing learning and professional development, continually seeking out opportunities to expand your knowledge and skills
Telix Pharmaceuticals

Telix Pharmaceuticals

View

Telix Pharmaceuticals develops and sells biopharmaceutical products aimed at improving the diagnosis and treatment of cancer and rare diseases. Their products use targeted radiation to enhance treatment decisions and offer personalized therapy for conditions that lack effective solutions. The company focuses on areas such as prostate and kidney cancers, glioma, sarcoma, and bone marrow conditioning. Telix has a global supply chain to manufacture and distribute its products to healthcare providers and patients. Unlike many competitors, Telix emphasizes sustainability, patient care, and ethical practices in its operations. The goal of Telix Pharmaceuticals is to create sustainable value for patients, shareholders, and employees while improving the quality of life for those affected by complex diseases.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Melbourne, Australia

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's priority review for TLX250-CDx highlights its potential in kidney cancer diagnostics.
  • Illuccix approval in the UK addresses PSMA-PET imaging agent shortages, boosting market share.
  • Promising IPAX-Linz study results enhance Telix's neuro-oncology portfolio with TLX101.

What critics are saying

  • Increased competition in targeted radiation therapy may impact Telix's market share.
  • Supply shortages of radioisotopes like gallium-68 could disrupt production and distribution.
  • Regulatory delays in key markets could hinder the commercial launch of new products.

What makes Telix Pharmaceuticals unique

  • Telix focuses on molecularly-targeted radiation therapy for prostate, renal, and glioblastoma cancers.
  • The company integrates sustainability and patient care into its biopharmaceutical operations.
  • Telix's global supply chain ensures worldwide availability of its diagnostic and therapeutic products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Annual Performance Bonus

Equity-Based Incentive Program

Paid Vacation

Paid Wellness Days

Hybrid Work Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Telix Pharmaceuticals
Apr 25th, 2025
AUA25: Telix to Showcase Urologic Pipeline at AUA: ProstACT Global, Illuccix(R) and Zircaix(R)

AUA25: Telix to showcase urologic pipeline at AUA: ProstACT Global, Illuccix(R) and zircaix(r).

PR Newswire
Apr 15th, 2025
Ipax-Linz Study Reports Promising Efficacy For Tlx101 Glioma Therapy Candidate

MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study[2]. IPAX-Linz is a single-arm Phase 2 investigator-initiated trial (IIT). IPAX-Linz evaluates the safety, tolerability and preliminary efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT). The target patient population is patients at first or second recurrence with high-grade gliomas (HGG), including glioblastoma. Treatment with TLX101 was well tolerated with no serious adverse events reported. IPAX-Linz demonstrated encouraging preliminary efficacy data, indicating a median overall survival (OS) of 12.4 months from the initiation of treatment with TLX101, or 32.2 months from initial diagnosis[3]

Siam News Network
Apr 6th, 2025
Telix Appoints Paul Schaffer as Chief Technology Officer

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2025 /PRNewswire/ - Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today.

Telix Pharmaceuticals
Apr 3rd, 2025
Anne Whitaker Appointed as Non-Executive Director

Telix today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 2025[1].

Pipeline Review
Apr 2nd, 2025
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

Telix holds the exclusive worldwide rights to develop and commercialize radiolabelled forms of olaratumab, which was originally developed by Eli Lilly and Company (Lilly).

INACTIVE